LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

LIN.US

477.98

-2.04%↓

BHP.UK

2,523

+2.85%↑

BHP.US

68.2

+4.73%↑

RIO.US

85.51

+2.94%↑

SCCO

159.5

+4.57%↑

Search

Avient Corp

Closed

SectorBasic materials

33.47 5.05

Overview

Share price change

24h

Current

Min

32.52

Max

33.81

Key metrics

By Trading Economics

Income

-16M

17M

Sales

-46M

761M

P/E

Sector Avg

38.596

34.302

EPS

0.56

Dividend yield

3.17

Profit margin

2.222

Employees

9,000

EBITDA

-2.9M

120M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+51.46% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.17%

2.86%

Next Earnings

5 May 2026

Next Dividend date

3 Apr 2026

Next Ex Dividend date

19 Jun 2026

Market Stats

By TradingEconomics

Market Cap

-425M

3.1B

Previous open

28.42

Previous close

33.47

News Sentiment

By Acuity

67%

33%

140 / 151 Basic materials

Technical Score

By Trading Central

Confidence

Neutral Evidence

Avient Corp Chart

Past performance is not a reliable indicator of future results.

Related News

23 Mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 Mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 Mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 Mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 Mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 Mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 Mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 Mar 2026, 22:42 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

23 Mar 2026, 22:42 UTC

Market Talk
Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 Mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 Mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 Mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 Mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 Mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 Mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 Mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 Mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 Mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 Mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 Mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 Mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 Mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 Mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 Mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 Mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 Mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 Mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 Mar 2026, 20:50 UTC

Market Talk
Earnings
Major News Events

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Avient Corp Forecast

Price Target

By TipRanks

51.46% upside

12 Months Forecast

Average 48.33 USD  51.46%

High 52 USD

Low 46 USD

Based on 4 Wall Street analysts offering 12 month price targets forAvient Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

1

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

33.48 / N/ASupport & Resistance

Short Term

Neutral Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

140 / 151 Basic materials

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Avient Corp

Avient Corporation operates as a formulator of material solutions in the United States, Canada, Mexico, Europe, South America, and Asia. It operates in two segments, Color, Additives and Inks; and Specialty Engineered Materials. The Color, Additives and Inks segment offers custom color and additive concentrates in solid and liquid form for thermoplastics, dispersions for thermosets, and specialty inks; custom-formulated liquid system, such as polyester, vinyl, natural rubber and latex, polyurethane, and silicone; and proprietary inks. Its products are used in medical and pharmaceutical devices, food packaging, personal care and cosmetics, transportation, building products, wire and cable, recreational and athletic apparel, construction and filtration, outdoor furniture, healthcare, textiles and appliances, and industrial markets. The Specialty Engineered Materials segment provides specialty polymer formulations, services, and solutions for designers, assemblers, and processors of thermoplastic materials. It sells its products through direct sales personnel, distributors, and commissioned sales agents. The company was formerly known as PolyOne Corporation and changed its name to Avient Corporation in June 2020. Avient Corporation was founded in 1885 and is headquartered in Avon Lake, Ohio.
help-icon Live chat